tiprankstipranks
Bristol-Myers Squibb Company (CH:BMY)
NYSE:BMY
Switzerland Market
BMY
Bristol-Myers Squibb
RESEARCH TOOLSreports

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

BMY Analyst Ratings

Moderate Buy
20Ratings
Moderate Buy
7 Buy
12 Hold
1 Sell
Based on 20 analysts giving stock ratings to
Bristol-Myers
Squibb
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

CHF50.16
▲(8.05% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is CHF50.16 with a high forecast of CHF59.59 and a low forecast of CHF31.78. The average price target represents a 8.05% change from the last price of CHF46.42.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"CHF30","45":"CHF45","60":"CHF60","37.5":"CHF37.5","52.5":"CHF52.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":59.59238775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF59.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.15692635625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF50.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.7826068,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF31.78</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,37.5,45,52.5,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.49,44.72864521153846,45.967290423076925,47.205935634615386,48.44458084615385,49.68322605769231,50.92187126923077,52.16051648076923,53.39916169230769,54.637806903846155,55.876452115384616,57.11509732692308,58.35374253846154,{"y":59.59238775,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.49,44.00284048894231,44.515680977884614,45.02852146682692,45.54136195576923,46.054202444711535,46.567042933653845,47.079883422596154,47.59272391153846,48.105564400480766,48.618404889423076,49.13124537836538,49.64408586730769,{"y":50.15692635625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.49,42.589431292307694,41.688862584615386,40.78829387692308,39.88772516923077,38.98715646153846,38.08658775384615,37.186019046153845,36.28545033846154,35.38488163076923,34.48431292307692,33.58374421538461,32.68317550769231,{"y":31.7826068,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.183,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.183,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.677,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.454,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.897,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.996,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.49,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF59.59Average Price TargetCHF50.16Lowest Price TargetCHF31.78
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on CH:BMY
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Guggenheim Analyst forecast on CH:BMY
Seamus Fernandez
Guggenheim
Guggenheim
CHF57.21
Buy
23.24%
Upside
Reiterated
06/05/26
Analysts Are Bullish on These Healthcare Stocks: ADC Therapeutics (ADCT), Bristol-Myers Squibb (BMY)
Piper Sandler Analyst forecast on CH:BMY
David Amsellem
Piper Sandler
Piper Sandler
CHF59.59
Buy
28.38%
Upside
Reiterated
06/03/26
Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler
UBS Analyst forecast on CH:BMY
Michael Yee
UBS
UBS
CHF55.62
Buy
19.82%
Upside
Reiterated
06/03/26
Bristol-Myers Squibb: Emerging Oncology Portfolio Supports Durable Growth; Buy Rating Reiterated with Unchanged $70 Price Target
Barclays Analyst forecast on CH:BMY
Emily Field
Barclays
Barclays
CHF59.59
Buy
28.38%
Upside
Reiterated
06/02/26
Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
Jefferies Analyst forecast on CH:BMY
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF55.62→CHF58
Buy
24.95%
Upside
Reiterated
06/01/26
Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Scotiabank Analyst forecast on CH:BMY
Louise Chen
Scotiabank
Scotiabank
CHF47.67
Hold
2.70%
Upside
Reiterated
06/01/26
Scotiabank Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Citi Analyst forecast on CH:BMY
Geoff Meacham
Citi
Citi
CHF52.44
Hold
12.97%
Upside
Reiterated
05/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Corcept Therapeutics (NASDAQ: CORT) and Taysha Gene Therapies (NASDAQ: TSHA)
Goldman Sachs Analyst forecast on CH:BMY
Asad Haider
Goldman Sachs
Goldman Sachs
CHF48.47
Hold
4.41%
Upside
Reiterated
05/28/26
Bristol-Myers Squibb: Hold Rating Reiterated as Analyst Maintains $61 Price Target Amid Near-Term Uncertainties and Long-Term Pipeline Potential
Morgan Stanley Analyst forecast on CH:BMY
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF31.78
Sell
-31.53%
Downside
Reiterated
05/26/26
Analysts Offer Insights on Healthcare Companies: MacroGenics (NASDAQ: MGNX), Bristol-Myers Squibb (NYSE: BMY) and Pelthos Therapeutics (NYSE MKT: PTHS)
Wells Fargo Analyst forecast on CH:BMY
Mohit Bansal
Wells Fargo
Wells Fargo
CHF47.67
Hold
2.70%
Upside
Reiterated
05/22/26
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY), BillionToOne, Inc. Class A (NASDAQ: BLLN) and Solventum Corporation (NYSE: SOLV)
Bank of America Securities Analyst forecast on CH:BMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF53.24
Buy
14.68%
Upside
Reiterated
05/20/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH) and Bristol-Myers Squibb (NYSE: BMY)
TD Cowen Analyst forecast on CH:BMY
Unknown Analyst
TD Cowen
Not Ranked
TD Cowen
CHF45.29
Hold
-2.43%
Downside
Reiterated
05/18/26
BMO Capital Analyst forecast on CH:BMY
Evan Seigerman
BMO Capital
BMO Capital
CHF47.67
Hold
2.70%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH), Bristol-Myers Squibb (NYSE: BMY) and Progyny (NASDAQ: PGNY)
Berenberg Bank Analyst forecast on CH:BMY
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
CHF47.67
Hold
2.70%
Upside
Reiterated
05/08/26
Berenberg Bank Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on CH:BMY
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Guggenheim Analyst forecast on CH:BMY
Seamus Fernandez
Guggenheim
Guggenheim
CHF57.21
Buy
23.24%
Upside
Reiterated
06/05/26
Analysts Are Bullish on These Healthcare Stocks: ADC Therapeutics (ADCT), Bristol-Myers Squibb (BMY)
Piper Sandler Analyst forecast on CH:BMY
David Amsellem
Piper Sandler
Piper Sandler
CHF59.59
Buy
28.38%
Upside
Reiterated
06/03/26
Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler
UBS Analyst forecast on CH:BMY
Michael Yee
UBS
UBS
CHF55.62
Buy
19.82%
Upside
Reiterated
06/03/26
Bristol-Myers Squibb: Emerging Oncology Portfolio Supports Durable Growth; Buy Rating Reiterated with Unchanged $70 Price Target
Barclays Analyst forecast on CH:BMY
Emily Field
Barclays
Barclays
CHF59.59
Buy
28.38%
Upside
Reiterated
06/02/26
Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
Jefferies Analyst forecast on CH:BMY
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF55.62→CHF58
Buy
24.95%
Upside
Reiterated
06/01/26
Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Scotiabank Analyst forecast on CH:BMY
Louise Chen
Scotiabank
Scotiabank
CHF47.67
Hold
2.70%
Upside
Reiterated
06/01/26
Scotiabank Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Citi Analyst forecast on CH:BMY
Geoff Meacham
Citi
Citi
CHF52.44
Hold
12.97%
Upside
Reiterated
05/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Corcept Therapeutics (NASDAQ: CORT) and Taysha Gene Therapies (NASDAQ: TSHA)
Goldman Sachs Analyst forecast on CH:BMY
Asad Haider
Goldman Sachs
Goldman Sachs
CHF48.47
Hold
4.41%
Upside
Reiterated
05/28/26
Bristol-Myers Squibb: Hold Rating Reiterated as Analyst Maintains $61 Price Target Amid Near-Term Uncertainties and Long-Term Pipeline Potential
Morgan Stanley Analyst forecast on CH:BMY
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF31.78
Sell
-31.53%
Downside
Reiterated
05/26/26
Analysts Offer Insights on Healthcare Companies: MacroGenics (NASDAQ: MGNX), Bristol-Myers Squibb (NYSE: BMY) and Pelthos Therapeutics (NYSE MKT: PTHS)
Wells Fargo Analyst forecast on CH:BMY
Mohit Bansal
Wells Fargo
Wells Fargo
CHF47.67
Hold
2.70%
Upside
Reiterated
05/22/26
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY), BillionToOne, Inc. Class A (NASDAQ: BLLN) and Solventum Corporation (NYSE: SOLV)
Bank of America Securities Analyst forecast on CH:BMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF53.24
Buy
14.68%
Upside
Reiterated
05/20/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH) and Bristol-Myers Squibb (NYSE: BMY)
TD Cowen Analyst forecast on CH:BMY
Unknown Analyst
TD Cowen
Not Ranked
TD Cowen
CHF45.29
Hold
-2.43%
Downside
Reiterated
05/18/26
BMO Capital Analyst forecast on CH:BMY
Evan Seigerman
BMO Capital
BMO Capital
CHF47.67
Hold
2.70%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH), Bristol-Myers Squibb (NYSE: BMY) and Progyny (NASDAQ: PGNY)
Berenberg Bank Analyst forecast on CH:BMY
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
CHF47.67
Hold
2.70%
Upside
Reiterated
05/08/26
Berenberg Bank Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

3 Months
Srikripa DevarakondaTruist Financial
Success Rate
11/15 ratings generated profit
73%
Average Return
+9.49%
Copying Srikripa Devarakonda's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +9.49% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
16/20 ratings generated profit
80%
Average Return
+9.86%
Copying David Risinger's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +9.86% per trade.
2 Years
Srikripa DevarakondaTruist Financial
Success Rate
13/15 ratings generated profit
87%
Average Return
+20.40%
Copying Srikripa Devarakonda's trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +20.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
24
16
13
14
19
Hold
33
27
27
30
26
Sell
4
2
1
1
1
Strong Sell
0
0
0
0
0
total
61
45
41
45
46
In the current month, BMY has received 19 Buy Ratings, 26 Hold Ratings, and 1 Sell Ratings. BMY average Analyst price target in the past 3 months is 50.16.
Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is CHF1.27 with a range of CHF1.17 to CHF1.36. The previous quarter’s EPS was CHF1.25. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.
Next quarter’s earnings estimate for BMY is CHF1.27 with a range of CHF1.17 to CHF1.36. The previous quarter’s EPS was CHF1.25. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is CHF9.27B with a range of CHF9.05B to CHF9.50B. The previous quarter’s sales results were CHF9.10B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.
Next quarter’s sales forecast for BMY is CHF9.27B with a range of CHF9.05B to CHF9.50B. The previous quarter’s sales results were CHF9.10B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Stock Forecast FAQ

What is CH:BMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb Company’s 12-month average price target is 50.16.
    What is CH:BMY’s upside potential, based on the analysts’ average price target?
    Bristol-Myers Squibb Company has 8.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Bristol-Myers Squibb Company a Buy, Sell or Hold?
          Bristol-Myers Squibb Company has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 12 hold ratings and 1 sell ratings.
            What is Bristol-Myers Squibb Company’s share price target?
            The average share price target for Bristol-Myers Squibb Company is 50.16. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF59.59 ,and the lowest forecast is CHF31.78. The average share price target represents 8.05% Increase from the current price of CHF46.42.
              What do analysts say about Bristol-Myers Squibb Company?
              Bristol-Myers Squibb Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of Bristol-Myers Squibb Company?
                To buy shares of CH:BMY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.